Drimenol synthases II

Info

Patent number: 10385363
Type: Grant
Filed: May 6, 2015
Date of Patent: Aug 20, 2019
Patent Publication Number: 20180251797
Assignee: Firmenich SA (Geneva)
Inventors: Yu-Hua Zhang (Shanghai), Michel Schalk (Geneva), Olivier Haefliger (Shanghai), Xiu-Feng He (Shanghai), Fabienne Deguerry (Geneva)
Primary Examiner: Iqbal H Chowdhury
Application Number: 15/330,814

Abstract

The present invention relates to a method of producing drimenol and/or drimenol derivatives by contacting at least one polypeptide with farnesyl diphosphate. The method may be performed in vitro or in vivo. The present invention also provides amino acid sequences of polypeptides useful in the method of the invention and nucleic acid encoding the polypeptides of the invention. The method further provides host cells or organisms genetically modified to express the polypeptides of the invention and useful to produce drimenol and/or drimenol derivatives.

Description

Description

TECHNICAL FIELD

The field relates to methods of producing Drimenol, said method comprising contacting at least one polypeptide with farnesyl pyrophosphate (FPP). In particular, said method may be carried out in vitro or in vivo to produce Drimenol, a very useful compound in the fields of perfumery. Also provided herein is an amino acid sequence of a polypeptide useful in the methods provided herein. A nucleic acid encoding the polypeptide of an embodiment herein and an expression vector containing said nucleic acid are also provided herein. A non-human host organism or a cell transformed to be used in the method of producing Drimenol is further provided herein.

BACKGROUND

Terpenes are found in most organisms (microorganisms, animals and plants). These compounds are made up of five carbon units called isoprene units and are classified by the number of these units present in their structure. Thus monoterpenes, sesquiterpenes and diterpenes are terpenes containing 10, 15 and 20 carbon atoms respectively. Sesquiterpenes, for example, are widely found in the plant kingdom. Many sesquiterpene molecules are known for their flavor and fragrance properties and their cosmetic, medicinal and antimicrobial effects. Numerous sesquiterpene hydrocarbons and sesquiterpenoids have been identified.

Biosynthetic production of terpenes involves enzymes called terpene synthases. There is virtually an infinity of sesquiterpene synthases present in the plant kingdom, all using the same substrate (farnesyl pyrophosphate, FPP) but having different product profiles. Genes and cDNAs encoding sesquiterpene synthases have been cloned and the corresponding recombinant enzymes characterized.

Currently the main source for Drimenol are plants naturally containing Drimenol and the contents of Drimenol in these natural sources are low. Chemical synthesis approaches have been developed but are still complex and not cost-effective.

SUMMARY

Provided herein is a method of producing Drimenol comprising:

- i) contacting a acyclic terpene pyrophosphate with a polypeptide having Drimenol synthase activity and having at least, or at least about 70% sequence identify to a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14 to produce the Drimenol; and
- ii) optionally isolating the Drimenol.

Further provided herein is an isolated polypeptide having Drimenol activity comprising an amino acid sequence having at least or at least about 70%, or more identity to amino acid sequence of a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14.

Also provided herein is an isolated nucleic acid molecule encoding a polypeptide having at least, or at least about 70% sequence identify to a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14

DESCRIPTION OF THE DRAWINGS

FIG. 1. GCMS analysis of the leaves of Drimys lanceolata and Drimys winteri.

FIG. 2. GCMS analysis of the sesquiterpenes produced by the recombinant DlTps589 in in-vitro assays. A. Total ion chromatogram of the sesquiterpene profile of an incubation of the recombinant DlTps589 protein with FPP. B. Negative control performed in the same conditions with E. coli cells transformed with an empty plasmid. C. Mass spectrum of the peak at 11.76 min. D. Mass spectrum of an authentic standard of (−)-drimenol.

FIG. 3. GCMS analysis of the sesquiterpenes produced in vivo by the recombinant DlTps589 in engineered bacteria cells. A. Total ion chromatogram. B. Mass spectrum of the peak at 11.49 min. C. Mass spectrum of an authentic standard of (−)-drimenol. The compound eluting at 10.98 min is farnesol produced by the DlTps589 enzyme or resulting from the hydrolysis of excess FPP produced by the E. coli cells.

FIG. 4. Structure of (−)-drimenol produced by the recombinant DlTps589 synthase.

FIG. 5. Chiral GC\FID chromatograms of (−)-drimenol produced by the recombinant enzyme (upper), racemic drimenol obtained chemically (middle) and authentic (−)-drimenol (lower).

FIG. 6. Total ion chromatogram of GCMS analysis of the sesquiterpenes produced in in-vitro assays by the recombinant proteins SCH51-3228-9 (A), SCH51-998-28 (B) or SCH52-13163-6 (C).

FIG. 7. Total ion chromatogram of GCMS analysis of the sesquiterpenes produced in vivo by engineered bacteria cells expressing the different recombinant proteins SCH51-3228-9 (A), SCH51-998-28 (B) or SCH52-13163-6 (C). The farnesol detected results from the hydrolysis of excess FPP produced by the E. coli cells or could be in part produced by the recombinant proteins.

DETAILED DESCRIPTION

For the descriptions herein and the appended claims, the use of “or” means “and/or” unless stated otherwise. Similarly, “comprise,” “comprises,” “comprising” “include,” “includes,” and “including” are interchangeable and not intended to be limiting.

It is to be further understood that where descriptions of various embodiments use the term “comprising,” those skilled in the art would understand that in some specific instances, an embodiment can be alternatively described using language “consisting essentially of” or “consisting of.” In one aspect, provided here is a method of producing Drimenol comprising:

i) contacting a acyclic terpene pyrophosphate, particularly farnesyl diphospate (FPP)) with a polypeptide having Drimenol synthase activity and having at least, or at least about 70%, particularly 75%, particularly 80%, particularly 85%, particularly 90%, particularly 95%, particularly 96%, particularly 97%, particularly 98% or particularly 99% or more sequence identify to a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14 to produce the Drimenol; and

ii) optionally isolating the Drimenol.

In one aspect, the Drimenol is isolated.

Further provided here is an isolated polypeptide having Drimenol activity comprising an amino acid sequence having at least or at least about 70%, particularly 75%, particularly 80%, particularly 85%, particularly 90%, particularly 95%, particularly 96%, particularly 97%, particularly 98% or more particularly 99% or more identity to amino acid sequence of a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14.

Further provided herein is an isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence having at least or at least about 70%, particularly 75%, particularly 80%, particularly 85%, particularly 90%, particularly 95%, particularly 96%, particularly 97%, particularly 98% or more particularly 99% or more identity to amino acid sequence of a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14.

Further provided herein a nucleic acid molecule comprising the sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6 SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID No: 13 and SEQ ID NO: 15.

Further provided here is a method as recited in claim 1 comprising the steps of transforming a host cell or non-human organism with a nucleic acid encoding a polypeptide having at least, or at least about, 70%, particularly 75%, particularly 80%, particularly 85%. particularly 90%, particularly 95%, particularly 96%, particularly 97%, particularly 98% or particularly 99% or more sequence identity of the sequence of a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14 and culturing the host cell or organism under conditions that allow for the production of the polypeptide.

Further provided is at least one vector comprising the nucleic acid molecules described.

Further provided herein is a vector selected from the group of a prokaryotic vector, viral vector and a eukaryotic vector.

Further provided here is a vector that is an expression vector.

As a “Drimenol synthase” or as a “polypeptide having a Drimenol synthase activity”, we mean here a polypeptide capable of catalyzing the synthesis of Drimenol, in the form of any of its stereoisomers or a mixture thereof, starting from an acyclic terpene pyrophosphate, particularly FPP. Drimenol may be the only product or may be part of a mixture of sesquiterpenes.

The ability of a polypeptide to catalyze the synthesis of a particular sesquiterpene (for example Drimenol) can be simply confirmed by performing the enzyme assay as detailed in Example 2 to 5.

Polypeptides are also meant to include truncated polypeptides provided that they keep their Drimenol synthase activity.

As intended herein below, “a nucleotide sequence obtained by modifying SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof” encompasses any sequence that has been obtained by changing the sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 12 or of the complement thereof using any method known in the art, for example by introducing any type of mutations such as deletion, insertion or substitution mutations. Examples of such methods are cited in the part of the description relative to the variant polypeptides and the methods to prepare them.

The percentage of identity between two peptidic or nucleotidic sequences is a function of the number of amino acids or nucleotide residues that are identical in the two sequences when an alignment of these two sequences has been generated. Identical residues are defined as residues that are the same in the two sequences in a given position of the alignment. The percentage of sequence identity, as used herein, is calculated from the optimal alignment by taking the number of residues identical between two sequences dividing it by the total number of residues in the shortest sequence and multiplying by 100. The optimal alignment is the alignment in which the percentage of identity is the highest possible. Gaps may be introduced into one or both sequences in one or more positions of the alignment to obtain the optimal alignment. These gaps are then taken into account as non-identical residues for the calculation of the percentage of sequence identity. Alignment for the purpose of determining the percentage of amino acid or nucleic acid sequence identity can be achieved in various ways using computer programs and for instance publicly available computer programs available on the world wide web. Preferably, the BLAST program (Tatiana et al, FEMS Microbiol Lett., 1999, 174:247-250, 1999) set to the default parameters, available from the National Center for Biotechnology Information (NCBI), can be used to obtain an optimal alignment of peptidic or nucleotidic sequences and to calculate the percentage of sequence identity.

ABBREVIATIONS USED

bp base pair

kb kilo base

BSA bovine serum albumin

DNA deoxyribonucleic acid

cDNA complementary DNA

DTT dithiothreitol

FID Flame ionization detector

FPP farnesyl pyrophosphate

GC gaseous chromatograph

IPTG isopropyl-D-thiogalacto-pyranoside

LB lysogeny broth

MS mass spectrometer

MVA mevalonic acid

PCR polymerase chain reaction

RMCE recombinase-mediated cassette exchange

3′-/5′-RACE 3′ and 5′ rapid amplification of cDNA ends

RNA ribonucleic acid

mRNA messenger ribonucleic acid

miRNA micro RNA

siRNA small interfering RNA

rRNA ribosomal RNA

tRNA transfer RNA

Definitions

The term “polypeptide” means an amino acid sequence of consecutively polymerized amino acid residues, for instance, at least 15 residues, at least 30 residues, at least 50 residues. In some embodiments provided herein, a polypeptide comprises an amino acid sequence that is an enzyme, or a fragment, or a variant thereof.

The term “isolated” polypeptide refers to an amino acid sequence that is removed from its natural environment by any method or combination of methods known in the art and includes recombinant, biochemical and synthetic methods.

The term “protein” refers to an amino acid sequence of any length wherein amino acids are linked by covalent peptide bonds, and includes oligopeptide, peptide, polypeptide and full length protein whether naturally occurring or synthetic.

The terms “Drimenol synthase” or “Drimenol synthase protein” refer to an enzyme that is capable of converting farnesyl diphosphate (FPP) to Drimenol.

The terms “biological function,” “function,” “biological activity” or “activity” refer to the ability of the Drimenol synthase to catalyze the formation of Drimenol from FPP.

The terms “nucleic acid sequence,” “nucleic acid,” and “polynucleotide” are used interchangeably meaning a sequence of nucleotides. A nucleic acid sequence may be a single-stranded or double-stranded deoxyribonucleotide, or ribonucleotide of any length, and include coding and non-coding sequences of a gene, exons, introns, sense and anti-sense complimentary sequences, genomic DNA, cDNA, miRNA, siRNA, mRNA, rRNA, tRNA, recombinant nucleic acid sequences, isolated and purified naturally occurring DNA and/or RNA sequences, synthetic DNA and RNA sequences, fragments, primers and nucleic acid probes. The skilled artisan is aware that the nucleic acid sequences of RNA are identical to the DNA sequences with the difference of thymine (T) being replaced by uracil (U).

An “isolated nucleic acid” or “isolated nucleic acid sequence” is defined as a nucleic acid or nucleic acid sequence that is in an environment different from that in which the nucleic acid or nucleic acid sequence naturally occurs. The term “naturally-occurring” as used herein as applied to a nucleic acid refers to a nucleic acid that is found in a cell in nature. For example, a nucleic acid sequence that is present in an organism, for instance in the cells of an organism, that can be isolated from a source in nature and which has not been intentionally modified by a human in the laboratory is naturally occurring.

“Recombinant nucleic acid sequence” are nucleic acid sequences that result from the use of laboratory methods (molecular cloning) to bring together genetic material from more than on source, creating a nucleic acid sequence that does not occur naturally and would not be otherwise found in biological organisms.

“Recombinant DNA technology” refers to molecular biology procedures to prepare a recomninant nucleic acid sequence as described, for instance, in Laboratory Manuals edited by Weigel and Glazebrook, 2002 Cold Spring Harbor Lab Press; and Sambrook et al., 1989 Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press.

The term “gene” means a DNA sequence comprising a region, which is transcribed into a RNA molecule, e.g., an mRNA in a cell, operably linked to suitable regulatory regions, e.g., a promoter. A gene may thus comprise several operably linked sequences, such as a promoter, a 5′ leader sequence comprising, e.g., sequences involved in translation initiation, a coding region of cDNA or genomic DNA, introns, exons, and/or a 3′non-translated sequence comprising, e.g., transcription termination sites.

A “chimeric gene” refers to any gene, which is not normally found in nature in a species, in particular, a gene in which one or more parts of the nucleic acid sequence are present that are not associated with each other in nature. For example the promoter is not associated in nature with part or all of the transcribed region or with another regulatory region. The term “chimeric gene” is understood to include expression constructs in which a promoter or transcription regulatory sequence is operably linked to one or more coding sequences or to an antisense, i.e., reverse complement of the sense strand, or inverted repeat sequence (sense and antisense, whereby the RNA transcript forms double stranded RNA upon transcription).

A “3′ UTR” or “3′ non-translated sequence” (also referred to as “3′ untranslated region,” or “3′end”) refers to the nucleic acid sequence found downstream of the coding sequence of a gene, which comprises for example a transcription termination site and (in most, but not all eukaryotic imRNAs) a polyadenylation signal such as AAUAAA or variants thereof. After termination of transcription, the mRNA transcript may be cleaved downstream of the polyadenylation signal and a poly(A) tail may be added, which is involved in the transport of the mRNA to the site of translation, e.g., cytoplasm.

“Expression of a gene” involves transcription of the gene and translation of the mRNA into a protein. Overexpression refers to the production of the gene product as measured by levels of mRNA, polypeptide and/or enzyme activity in transgenic cells or organisms that exceeds levels of production in non-transformed cells or organisms of a similar genetic background.

“Expression vector” as used herein means a nucleic acid molecule engineered using molecular biology methods and recombinant DNA technology for delivery of foreign or exogenous DNA into a host cell. The expression vector typically includes sequences required for proper transcription of the nucleotide sequence. The coding region usually codes for a protein of interest but may also code for an RNA, e.g., an antisense RNA, siRNA and the like.

An “expression vector” as used herein includes any linear or circular recombinant vector including but not limited to viral vectors, bacteriophages and plasmids. The skilled person is capable of selecting a suitable vector according to the expression system. In one embodiment, the expression vector includes the nucleic acid of an embodiment herein operably linked to at least one regulatory sequence, which controls transcription, translation, initiation and termination, such as a transcriptional promoter, operator or enhancer, or an mRNA ribosomal binding site and, optionally, including at least one selection marker. Nucleotide sequences are “operably linked” when the regulatory sequence functionally relates to the nucleic acid of an embodiment herein. “Regulatory sequence” refers to a nucleic acid sequence that determines expression level of the nucleic acid sequences of an embodiment herein and is capable of regulating the rate of transcription of the nucleic acid sequence operably linked to the regulatory sequence. Regulatory sequences comprise promoters, enhancers, transcription factors, promoter elements and the like.

“Promoter” refers to a nucleic acid sequence that controls the expression of a coding sequence by providing a binding site for RNA polymerase and other factors required for proper transcription including without limitation transcription factor binding sites, repressor and activator protein binding sites. The meaning of the term promoter also include the term “promoter regulatory sequence”. Promoter regulatory sequences may include upstream and downstream elements that may influences transcription, RNA processing or stability of the associated coding nucleic acid sequence. Promoters include naturally-derived and synthetic sequences. The coding nucleic acid sequences is usually located downstream of the promoter with respect to the direction of the transcription starting at the transcription initiation site.

The term “constitutive promoter” refers to an unregulated promoter that allows for continual transcription of the nucleic acid sequence it is operably linked to.

As used herein, the term “operably linked” refers to a linkage of polynucleotide elements in a functional relationship. A nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter, or rather a transcription regulatory sequence, is operably linked to a coding sequence if it affects the transcription of the coding sequence. Operably linked means that the DNA sequences being linked are typically contiguous. The nucleotide sequence associated with the promoter sequence may be of homologous or heterologous origin with respect to the plant to be transformed. The sequence also may be entirely or partially synthetic. Regardless of the origin, the nucleic acid sequence associated with the promoter sequence will be expressed or silenced in accordance with promoter properties to which it is linked after binding to the polypeptide of an embodiment herein. The associated nucleic acid may code for a protein that is desired to be expressed or suppressed throughout the organism at all times or, alternatively, at a specific time or in specific tissues, cells, or cell compartment. Such nucleotide sequences particularly encode proteins conferring desirable phenotypic traits to the host cells or organism altered or transformed therewith. More particularly, the associated nucleotide sequence leads to the production of Drimenol in the organism. Particularly, the nucleotide sequence encodes Drimenol synthase.

“Target peptide” refers to an amino acid sequence which targets a protein, or polypeptide to intracellular organelles, i.e., mitochondria, or plastids, or to the extracellular space (secretion signal peptide). A nucleic acid sequence encoding a target peptide may be fused to the nucleic acid sequence encoding the amino terminal end, e.g., N-terminal end, of the protein or polypeptide, or may be used to replace a native targeting polypeptide.

The term “primer” refers to a short nucleic acid sequence that is hybridized to a template nucleic acid sequence and is used for polymerization of a nucleic acid sequence complementary to the template.

As used herein, the term “host cell” or “transformed cell” refers to a cell (or organism) altered to harbor at least one nucleic acid molecule, for instance, a recombinant gene encoding a desired protein or nucleic acid sequence which upon transcription yields a Drimenol synthase protein useful to produce Drimenol. The host cell is particularly a bacterial cell, a fungal cell or a plant cell. The host cell may contain a recombinant gene which has been integrated into the nuclear or organelle genomes of the host cell. Alternatively, the host may contain the recombinant gene extra-chromosomally. Homologous sequences include orthologous or paralogous sequences. Methods of identifying orthologs or paralogs including phylogenetic methods, sequence similarity and hybridization methods are known in the art and are described herein.

Paralogs result from gene duplication that gives rise to two or more genes with similar sequences and similar functions. Paralogs typically cluster together and are formed by duplications of genes within related plant species. Paralogs are found in groups of similar genes using pair-wise Blast analysis or during phylogenetic analysis of gene families using programs such as CLUSTAL. In paralogs, consensus sequences can be identified characteristic to sequences within related genes and having similar functions of the genes.

Orthologs, or orthologous sequences, are sequences similar to each other because they are found in species that descended from a common ancestor. For instance, plant species that have common ancestors are known to contain many enzymes that have similar sequences and functions. The skilled artisan can identify orthologous sequences and predict the functions of the orthologs, for example, by constructing a polygenic tree for a gene family of one species using CLUSTAL or BLAST programs. A method for identifying or confirming similar functions among homologous sequences is by comparing of the transcript profiles in plants overexpressing or lacking (in knockouts/knockdowns) related polypeptides. The skilled person will understand that genes having similar transcript profiles, with greater than 50% regulated transcripts in common, or with greater than 70% regulated transcripts in common, or greater than 90% regulated transcripts in common will have similar functions. Homologs, paralogs, orthologs and any other variants of the sequences herein are expected to function in a similar manner by making plants producing Drimenol synthase proteins.

An embodiment of the provided herein provides amino acid sequences of Drimenol synthase proteins including orthologs and paralogs as well as methods for identifying and isolating orthologs and paralogs of the Drimenol synthases in other organisms. Particularly, so identified orthologs and paralogs of the Drimenol synthase retain Drimenol synthase activity and are capable of producing Drimenol starting from FPP precursors.

The term “selectable marker” refers to any gene which upon expression may be used to select a cell or cells that include the selectable marker. Examples of selectable markers are described below. The skilled artisan will know that different antibiotic, fungicide, auxotrophic or herbicide selectable markers are applicable to different target species.

“Drimenol” for purposes of this application refers to (−)-drimenol (CAS: 468-68-8).

The term “organism” refers to any non-human multicellular or unicellular organisms such as a plant, or a microorganism. Particularly, a micro-organism is a bacterium, a yeast, an algae or a fungus. The term “plant” is used interchangeably to include plant cells including plant protoplasts, plant tissues, plant cell tissue cultures giving rise to regenerated plants, or parts of plants, or plant organs such as roots, stems, leaves, flowers, pollen, ovules, embryos, fruits and the like. Any plant can be used to carry out the methods of an embodiment herein.

The polypeptide to be contacted with an acyclic pyrophosphate, e.g. FPP, in vitro can be obtained by extraction from any organism expressing it, using standard protein or enzyme extraction technologies. If the host organism is an unicellular organism or cell releasing the polypeptide of an embodiment herein into the culture medium, the polypeptide may simply be collected from the culture medium, for example by centrifugation, optionally followed by washing steps and re-suspension in suitable buffer solutions. If the organism or cell accumulates the polypeptide within its cells, the polypeptide may be obtained by disruption or lysis of the cells and further extraction of the polypeptide from the cell lysate.

The polypeptide having a Drimenol synthase activity, either in an isolated form or together with other proteins, for example in a crude protein extract obtained from cultured cells or microorganisms, may then be suspended in a buffer solution at optimal pH. If adequate, salts, DTT, inorganic cations and other kinds of enzymatic co-factors, may be added in order to optimize enzyme activity. The precursor FPP is added to the polypeptide suspension, which is then incubated at optimal temperature, for example between 15 and 40° C., particularly between 25 and 35° C., more particularly at 30° C. After incubation, the Drimenol produced may be isolated from the incubated solution by standard isolation procedures, such as solvent extraction and distillation, optionally after removal of polypeptides from the solution.

According to another particularly embodiment, the method of any of the above-described embodiments is carried out in vivo. In this case, step a) comprises cultivating a non-human host organism or cell capable of producing FPP and transformed to express at least one polypeptide comprising an amino acid sequence at least 70% identical to a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14 and having a Drimenol synthase activity, under conditions conducive to the production of Drimenol.

According to a more particular embodiment, the method further comprises, prior to step a), transforming a non human organism or cell capable of producing FPP with at least one nucleic acid encoding a polypeptide comprising an amino acid sequence at least 70% identical to a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14 and having a Drimenol synthase activity, so that said organism expresses said polypeptide.

These embodiments provided herein are particularly advantageous since it is possible to carry out the method in vivo without previously isolating the polypeptide. The reaction occurs directly within the organism or cell transformed to express said polypeptide.

According to a more particular embodiment at least one nucleic acid used in any of the above embodiments comprises a nucleotide sequence that has been obtained by modifying SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof. According to another embodiment, the at least one nucleic acid is isolated from a plant of the Winteraceae family or the Canellaceae family, particularly from Drimys Winteri or Drimys lanceolata.

The organism or cell is meant to “express” a polypeptide, provided that the organism or cell is transformed to harbor a nucleic acid encoding said polypeptide, this nucleic acid is transcribed to mRNA and the polypeptide is found in the host organism or cell. The term “express” encompasses “heterologously express” and “over-express”, the latter referring to levels of mRNA, polypeptide and/or enzyme activity over and above what is measured in a non-transformed organism or cell. A more detailed description of suitable methods to transform a non-human host organism or cell will be described later on in the part of the specification that is dedicated to such transformed non-human host organisms or cells.

A particular organism or cell is meant to be “capable of producing FPP” when it produces FPP naturally or when it does not produce FPP naturally but is transformed to produce FPP, either prior to the transformation with a nucleic acid as described herein or together with said nucleic acid. Organisms or cells transformed to produce a higher amount of FPP than the naturally occurring organism or cell are also encompassed by the “organisms or cells capable of producing FPP”. Methods to transform organisms, for example microorganisms, so that they produce FPP are already known in the art.

To carry out an embodiment herein in vivo, the host organism or cell is cultivated under conditions conducive to the production of Drimenol. Accordingly, if the host is a transgenic plant, optimal growth conditions are provided, such as optimal light, water and nutrient conditions, for example. If the host is a unicellular organism, conditions conducive to the production of Drimenol may comprise addition of suitable cofactors to the culture medium of the host. In addition, a culture medium may be selected, so as to maximize Drimenol synthesis. Optimal culture conditions are described in a more detailed manner in the following Examples.

Non-human host organisms suitable to carry out the method of an embodiment herein in vivo may be any non-human multicellular or unicellular organisms. In a particular embodiment, the non-human host organism used to carry out an embodiment herein in vivo is a plant, a prokaryote or a fungus. Any plant, prokaryote or fungus can be used. Particularly useful plants are those that naturally produce high amounts of terpenes. In a more particular embodiment the non-human host organism used to carry out the method of an embodiment herein in vivo is a microorganism. Any microorganism can be used but according to an even more particular embodiment said microorganism is a bacteria or yeast. Most particularly, said bacteria is E. coli and said yeast is Saccharomyces cerevisiae.

Some of these organisms do not produce FPP naturally. To be suitable to carry out the method of an embodiment herein, these organisms have to be transformed to produce said precursor. They can be so transformed either before the modification with the nucleic acid described according to any of the above embodiments or simultaneously, as explained above.

Isolated higher eukaryotic cells can also be used, instead of complete organisms, as hosts to carry out the method of an embodiment herein in vivo. Suitable eukaryotic cells may be any non-human cell, but are particularly plant or fungal cells.

In another particular embodiment, the polypeptide consists of an amino acid sequence at least at least 70%, particularly at least 75%, particularly at least 80%, particularly at least 85%, particularly at least 90%, particularly at least 95%, particularly at least 96%, particularly at least 97%, particularly at least 98% and even more particularly at least 99% sequence identity to a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14. In an even more particular embodiment, said polypeptide consists of SEQ ID.

According to another particular embodiment, the at least one polypeptide having a Drimenol synthase activity used in any of the above-described embodiments or encoded by the nucleic acid used in any of the above-described embodiments comprises an amino acid sequence that is a variant of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 14 obtained by genetic engineering, provided that said variant keeps its Drimenol synthase activity, as defined above and has the required percentage of identity to SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 14. In other terms, said polypeptide particularly comprises an amino acid sequence encoded by a nucleotide sequence that has been obtained by modifying SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof. According to a more particular embodiment, the at least one polypeptide having a Drimenol synthase activity used in any of the above-described embodiments or encoded by the nucleic acid used in any of the above-described embodiments consists of an amino acid sequence that is a variant of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 14 obtained by genetic engineering, i.e. an amino acid sequence encoded by a nucleotide sequence that has been obtained by modifying modifying SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof.

According to another particular embodiment, the at least one polypeptide having a Drimenol synthase activity used in any of the above-described embodiments or encoded by the nucleic acid used in any of the above-described embodiments is a variant of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 14 that can be found naturally in other organisms, such as other plant species, provided that it keeps its Drimenol synthase activity as defined above and has the required percentage of identity to of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 14.

As used herein, the polypeptide is intended as a polypeptide or peptide fragment that encompasses the amino acid sequences identified herein, as well as truncated or variant polypeptides, provided that they keep their Drimenol synthase activity as defined above and that they share at least the defined percentage of identity with the corresponding fragment of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 14.

Examples of variant polypeptides are naturally occurring proteins that result from alternate mRNA splicing events or from proteolytic cleavage of the polypeptides described herein. Variations attributable to proteolysis include, for example, differences in the N- or C-termini upon expression in different types of host cells, due to proteolytic removal of one or more terminal amino acids from the polypeptides of an embodiment herein. Polypeptides encoded by a nucleic acid obtained by natural or artificial mutation of a nucleic acid of an embodiment herein, as described thereafter, are also encompassed by an embodiment herein.

Polypeptide variants resulting from a fusion of additional peptide sequences at the amino and carboxyl terminal ends can also be used in the methods of an embodiment herein. In particular such a fusion can enhance expression of the polypeptides, be useful in the purification of the protein or improve the enzymatic activity of the polypeptide in a desired environment or expression system. Such additional peptide sequences may be signal peptides, for example. Accordingly, encompassed herein are methods using variant polypeptides, such as those obtained by fusion with other oligo- or polypeptides and/or those which are linked to signal peptides. Polypeptides resulting from a fusion with another functional protein, such as another protein from the terpene biosynthesis pathway, can also be advantageously be used in the methods of an embodiment herein.

According to another embodiment, the at least one polypeptide having a Drimenol synthase activity used in any of the above-described embodiments or encoded by the nucleic acid used in any of the above-described embodiments is isolated from a plant of the Winteraceae family or the Canellaceae family, particularly from Drimys Winteri or Drimys lanceolata.

An important tool to carry out the method of an embodiment herein is the polypeptide itself. A polypeptide having a Drimenol synthase activity and comprising an amino acid sequence at least 70% identical to SEQ ID NO:2 is therefore provided herein.

According to a particular embodiment, the polypeptide is capable of producing a mixture of sesquiterpenes wherein Drimenol represents at least 20%, particularly at least 30%, particularly at least 35%, particularly at least 90%, particularly at least 95%, more particularly at least 98% of the sesquiterpenes produced. In another aspect provided here, the Drimenol is produced with greater than or equal to 95%, more particularly 98% selectivity.

According to a particular embodiment, the polypeptide comprises an amino acid sequence at least 70%, particularly at least 75%, particularly at least 80%, particularly at least 85%, particularly at least 90%, particularly at least 95%, particularly at least 96%, particularly at least 97%, particularly at least 98% and even more particularly at least 99% identical to a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14. According to a more particular embodiment, the polypeptide comprises amino acid sequence selected from the group consisting of of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14

According to another particular embodiment, the polypeptide consists of an amino acid sequence at least 70%, particularly at least 75%, particularly at least 80%, particularly at least 85%, particularly at least 90%, particularly at least 95%, particularly at least 96%, particularly at least 97%, particularly at least 98% and even more particularly at least 99% identical to a sequence selected from the group consisting of of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 14. According to a more particular embodiment, the polypeptide consists of an amino acid selected from the group consisting of of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 14.

The at least one polypeptide comprises an amino acid sequence that is a variant of SEQ ID NO:2, either obtained by genetic engineering or found naturally in Drimys plants or in other plant species. In other terms, when the variant polypeptide is obtained by genetic engineering, said polypeptide comprises an amino acid sequence encoded by a nucleotide sequence that has been obtained by modifying SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof. According to a more particular embodiment, the at least one polypeptide having a Drimenol synthase activity consists of an amino acid sequence that is a variant of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 14 obtained by genetic engineering, i.e. an amino acid sequence encoded by a nucleotide sequence that has been obtained by modifying SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof.

According to another embodiment, the polypeptide is isolated from a plant of the Winteraceae family or the Canellaceae family, particularly from Drimys Winteri or Drimys lanceolata. As used herein, the polypeptide is intended as a polypeptide or peptide fragment that encompasses the amino acid sequence identified herein, as well as truncated or variant polypeptides, provided that they keep their activity as defined above and that they share at least the defined percentage of identity with the corresponding fragment of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 14.

As mentioned above, the nucleic acid encoding the polypeptide of an embodiment herein is a useful tool to modify non-human host organisms or cells intended to be used when the method is carried out in vivo.

A nucleic acid encoding a polypeptide according to any of the above-described embodiments is therefore also provided herein.

According to a particular embodiment, the nucleic acid comprises a nucleotide sequence at least 50%, particularly at least 55%, particularly at least 60%, particularly at least 65%, particularly at least 70%, particularly at least 75%, particularly at least 80%, particularly at least 85%, particularly at least 90%, more particularly at least 95% particularly at least 96%, particularly at least 97%, particularly at least 98%, and even more particularly at least 99% identical to a sequence selected from the group consisting of a sequence selected from the group consisting of NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof. According to a more particular embodiment, the nucleic acid comprises the nucleotide sequence selected from the group consisting of NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 thereof.

According to another particular embodiment, the nucleic acid consists of a nucleotide sequence at least 70%, particularly at least 75%, particularly at least 80%, particularly at least 85%, particularly at least 90%, particularly at least 95%, particularly at least 96%, particularly at least 97%, particularly at least 98% and even more particularly at least 99% or more identity to a sequence selected from the group consisting NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof. According to an even more particular embodiment, the nucleic acid consists of a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof.

The nucleic acid of an embodiment herein can be defined as including deoxyribonucleotide or ribonucleotide polymers in either single- or double-stranded form (DNA and/or RNA). The terms “nucleotide sequence” should also be understood as comprising a polynucleotide molecule or an oligonucleotide molecule in the form of a separate fragment or as a component of a larger nucleic acid. Nucleic acids of an embodiment herein also encompass certain isolated nucleotide sequences including those that are substantially free from contaminating endogenous material. The nucleic acid of an embodiment herein may be truncated, provided that it encodes a polypeptide encompassed herein, as described above.

In one embodiment, the nucleic acid of an embodiment herein can be either present naturally in plants of the Drimys species or other species, or be obtained by modifying SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof. Particularly said nucleic acid consists of a nucleotide sequence that has been obtained by modifying SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof.

The nucleic acids comprising a sequence obtained by mutation of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof are encompassed by an embodiment herein, provided that the sequences they comprise share at least the defined percentage of identity with the corresponding fragments of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or the complement thereof and provided that they encode a polypeptide having a Drimenol synthase activity, as defined in any of the above embodiments. Mutations may be any kind of mutations of these nucleic acids, such as point mutations, deletion mutations, insertion mutations and/or frame shift mutations. A variant nucleic acid may be prepared in order to adapt its nucleotide sequence to a specific expression system. For example, bacterial expression systems are known to more efficiently express polypeptides if amino acids are encoded by particular codons.

Due to the degeneracy of the genetic code, more than one codon may encode the same amino acid sequence, multiple nucleic acid sequences can code for the same protein or polypeptide, all these DNA sequences being encompassed by an embodiment herein. Where appropriate, the nucleic acid sequences encoding the Drimenol synthase may be optimized for increased expression in the host cell. For example, nucleotides of an embodiment herein may be synthesized using codons particular by a host for improved expression.

Another important tool for transforming host organisms or cells suitable to carry out the method of an embodiment herein in vivo is an expression vector comprising a nucleic acid according to any embodiment of an embodiment herein. Such a vector is therefore also provided herein.

The expression vectors provided herein may be used in the methods for preparing a genetically transformed host organism and/or cell, in host organisms and/or cells harboring the nucleic acids of an embodiment herein and in the methods for making polypeptides having a Drimenol synthase activity, as disclosed further below.

Recombinant non-human host organisms and cells transformed to harbor at least one nucleic acid of an embodiment herein so that it heterologously expresses or over-expresses at least one polypeptide of an embodiment herein are also very useful tools to carry out the method of an embodiment herein. Such non-human host organisms and cells are therefore also provided herein.

A nucleic acid according to any of the above-described embodiments can be used to transform the non-human host organisms and cells and the expressed polypeptide can be any of the above-described polypeptides.

Non-human host organisms of an embodiment herein may be any non-human multicellular or unicellular organisms. In a particular embodiment, the non-human host organism is a plant, a prokaryote or a fungus. Any plant, prokaryote or fungus is suitable to be transformed according to the methods provided herein. Particularly useful plants are those that naturally produce high amounts of terpenes.

In a more particular embodiment the non-human host organism is a microorganism. Any microorganism is suitable to be used herein, but according to an even more particular embodiment said microorganism is a bacteria or yeast. Most particularly, said bacteria is E. coli and said yeast is Saccharomyces cerevisiae.

Isolated higher eukaryotic cells can also be transformed, instead of complete organisms. As higher eukaryotic cells, we mean here any non-human eukaryotic cell except yeast cells. Particular higher eukaryotic cells are plant cells or fungal cells.

A variant may also differ from the polypeptide of an embodiment herein by attachment of modifying groups which are covalently or non-covalently linked to the polypeptide backbone. The variant also includes a polypeptide which differs from the polypeptide described herein by introduced N-linked or O-linked glycosylation sites, and/or an addition of cysteine residues. The skilled artisan will recognise how to modify an amino acid sequence and preserve biological activity.

The functionality or activity of any Drimenol synthase protein, variant or fragment, may be determined using various methods. For example, transient or stable overexpression in plant, bacterial or yeast cells can be used to test whether the protein has activity, i.e., produces Drimenol from FPP precursors. Drimenol synthase activity may be assessed in a microbial expression system, such as the assay described in Example 2 or 3 herein on the production of Drimenol, indicating functionality. A variant or derivative of a Drimenol synthase polypeptide of an embodiment herein retains an ability to produce Drimenol from FPP precursors Amino acid sequence variants of the Drimenol synthases provided herein may have additional desirable biological functions including, e.g., altered substrate utilization, reaction kinetics, product distribution or other alterations.

An embodiment herein provides polypeptides of an embodiment herein to be used in a method to produce Drimenol by contacting an FPP precursor with the polypeptides of an embodiment herein either in vitro or in vivo.

Provided herein is also an isolated, recombinant or synthetic polynucleotide encoding a polypeptide or variant polypeptide provided herein.

An embodiment of an embodiment herein provides an isolated, recombinant or synthetic nucleic acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 or a variant thereof encoding for a Drimenol synthase having the amino acid sequence which is at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to a amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 14 or fragments thereof that catalyze production of Drimenol in a cell from a FPP precursor. Embodiments provided herein include, but are not limited to cDNA, genomic DNA and RNA sequences. Any nucleic acid sequence encoding the Drimenol synthase or variants thereof is referred herein as a Drimenol synthase encoding sequence.

According to a particular embodiment, the nucleic acid of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 SEQ is the coding sequence of a Drimenol synthase gene encoding the Drimenol synthase obtained as described in the Examples.

A fragment of a polynucleotide of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 refers to contiguous nucleotides that is particularly at least 15 bp, at least 30 bp, at least 40 bp, at least 50 bp and/or at least 60 bp in length of the polynucleotide of an embodiment herein herein. Particularly the fragment of a polynucleotide comprises at least 25, more particularly at least 50, more particularly at least 75, more particularly at least 100, more particularly at least 150, more particularly at least 200, more particularly at least 300, more particularly at least 400, more particularly at least 500, more particularly at least 600, more particularly at least 700, more particularly at least 800, more particularly at least 900, more particularly at least 1000 contiguous nucleotides of the polynucleotide of the an embodiment herein. Without being limited, the fragment of the polynucleotides herein may be used as a PCR primer, and/or as a probe, or for anti-sense gene silencing or RNAi.

It is clear to the person skilled in the art that genes, including the polynucleotides of an embodiment herein, can be cloned on basis of the available nucleotide sequence information, such as found in the attached sequence listing, by methods known in the art. These include e.g. the design of DNA primers representing the flanking sequences of such gene of which one is generated in sense orientations and which initiates synthesis of the sense strand and the other is created in reverse complementary fashion and generates the antisense strand. Thermo stable DNA polymerases such as those used in polymerase chain reaction are commonly used to carry out such experiments. Alternatively, DNA sequences representing genes can be chemically synthesized and subsequently introduced in DNA vector molecules that can be multiplied by e.g. compatible bacteria such as e.g. E. coli.

In a related embodiment of an embodiment herein, PCR primers and/or probes for detecting nucleic acid sequences encoding a Drimenol synthase are provided. The skilled artisan will be aware of methods to synthesize degenerate or specific PCR primer pairs to amplify a nucleic acid sequence encoding the Drimenol synthase or fragments thereof, based on SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15. A detection kit for nucleic acid sequences encoding the Drimenol synthase may include primers and/or probes specific for nucleic acid sequences encoding the Drimenol synthase, and an associated protocol to use the primers and/or probes to detect nucleic acid sequences encoding the Drimenol synthase in a sample. Such detection kits may be used to determine whether a plant has been modified, i.e., transformed with a sequence encoding the Drimenol synthase.

Provided herein are nucleic acid sequences obtained by mutations of NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 such mutations can be routinely made. It is clear to the skilled artisan that mutations, deletions, insertions, and/or substitutions of one or more nucleotides can be introduced into the DNA sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15. Generally, a mutation is a change in the DNA sequence of a gene that can alter the amino acid sequence of the polypeptide produced.

To test a function of variant DNA sequences according to an embodiment herein, the sequence of interest is operably linked to a selectable or screenable marker gene and expression of the reporter gene is tested in transient expression assays with protoplasts or in stably transformed plants. The skilled artisan will recognize that DNA sequences capable of driving expression are built as modules. Accordingly, expression levels from shorter DNA fragments may be different than the one from the longest fragment and may be different from each other. Further provided herein are also functional equivalents of the nucleic acid sequence coding the Drimenol synthase proteins, i.e., nucleotide sequences that hybridize under stringent conditions to the nucleic acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15. The skilled artisan will be aware of methods to identify homologous sequences in other organisms and methods (identified in the Definition section herein) to determine the percentage of sequence identity between homologous sequences. Such newly identified to DNA molecules then can be sequenced and the sequence can be compared with the nucleic acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15 and tested for functional equivalence. Provided herein are are DNA molecules having at least 70% particularly 75%, particularly 80%, particularly 85%, particularly 90%, particularly 95%, particularly 96% particularly 97% particularly 98%, or more particularly 99% or more sequence identity to the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15

A related embodiment provides a nucleic acid sequence which is complementary to the nucleic acid sequence according to SEQ ID NO:1 or SEQ ID NO:3, such as inhibitory RNAs, or nucleic acid sequence which hybridizes under stringent conditions to at least part of the nucleotide sequence according to NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 15

An alternative embodiment of provided herein provides a method to alter gene expression in a host cell. For instance, the polynucleotide of an embodiment herein may be enhanced or overexpressed or induced in certain contexts (e.g. following insect bites or stings or upon exposure to a certain temperature) in a host cell or host organism.

Alteration of expression of a polynucleotide provided hereinalso results in “ectopic expression” which is a different expression pattern in an altered and in a control or wild-type organism. Alteration of expression occurs from interactions of polypeptide of an embodiment herein with exogenous or endogenous modulators, or as a result of chemical modification of the polypeptide. The term also refers to an altered expression pattern of the polynucleotide of an embodiment herein which is altered below the detection level or completely suppressed activity.

In one embodiment, several Drimenol synthase encoding nucleic acid sequences are co-expressed in a single host, particularly under control of different promoters. Alternatively, several Drimenol synthase protein encoding nucleic acid sequences can be present on a single transformation vector or be co-transformed at the same time using separate vectors and selecting transformants comprising both chimeric genes. Similarly, one or more Drimenol synthase encoding genes may be expressed in a single plant together with other chimeric genes, for example encoding other proteins which enhance insect pest resistance, or others.

The nucleic acid sequences of an embodiment herein encoding Drimenol synthase proteins can be inserted in expression vectors and/or be contained in chimeric genes inserted in expression vectors, to produce Drimenol synthase proteins in a host cell or host organism. The vectors for inserting transgenes into the genome of host cells are well known in the art and include plasmids, viruses, cosmids and artificial chromosomes. Binary or co-integration vectors into which a chimeric gene is inserted are also used for transforming host cells.

An embodiment of the provided herein provides recombinant expression vectors comprising a nucleic acid sequence of a Drimenol synthase gene, or a chimeric gene comprising a nucleic acid sequence of a Drimenol synthase gene, operably linked to associated nucleic acid sequences such as, for instance, promoter sequences. For example, a chimeric gene comprising a nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:3 may be operably linked to a promoter sequence suitable for expression in plant cells, bacterial cells or fungal cells, optionally linked to a 3′ non-translated nucleic acid sequence.

Alternatively, the promoter sequence may already be present in a vector so that the nucleic acid sequence which is to be transcribed is inserted into the vector downstream of the promoter sequence. Vectors are typically engineered to have an origin of replication, a multiple cloning site, and a selectable marker.

The following examples are illustrative only and are not intended to limit the scope of the claims or embodiments provided herein.

EXAMPLES Example 1

Drimys lanceolata and Drimys winteri Plant Material and Leaf Transcriptome Sequencing.

Drimys winteri and Drimys lanceolata plants were obtained from Bluebell Nursery (Leicestershire, UK). For analysis of the composition in terpene molecules, the leaves were collected and solvent extracted using MTBE (methyl tert-butyl ether). The extract was analyzed by GCMS using an Agilent 6890 Series GC system connected to an Agilent 5975 mass detector. The GC was equipped with 0.25 mm inner diameter by 30 m DB-1 ms capillary column (Agilent). The carrier gas was He at a constant flow of 1 mL/min. The initial oven temperature was 50° C. (1 min hold) followed by a gradient of 10° C./min to 300° C. The injection was made in a split/splitless injector set at 260° C. and used in splitless mode. The identification of the products was based on the comparison of the mass spectra and retention indices with authentic standards and internal mass spectra databases. The leaves of the two plants contained significant quantities of drimane sesquiterpene compounds including (−)-drimenol, polygodial and epipolygodial (FIG. 1).

Small leaves of D. winteri and D. lanceolata were thus taken for transcriptome analysis. Total RNA was extracted using the Concert™ Plant RNA Reagent (Invitrogen). This total RNA was processed using the Illumina Total RNA-Seq technique and the Illumina HiSeq 2000 sequencer. A total of 101 and 105 millions of paired-reads of 2×100 bp were generated for D. winteri and D. lanceolata, respectively. The reads were assembled using the Velvet de novo genomic assembler and the Oases software. For D. winteri 40,586 contigs with an average size of 1,080 bp were assembled and for D. lanceolate 28,255 contigs with an average size of 1,179 bp were obtained. The contigs were search using the tBlastn algorithm (Altschul et al, J. Mol. Biol. 215, 403-410, 1990) and using as query the amino acid sequences of known sesquiterpene synthases. This approach provided the sequences for 37 new putative sesquiterpene synthases. The enzymatic activity of these synthases were evaluated as described in the following examples for the synthases showing Drimenol synthase activity.

Example 2. Functional Expression and Characterization of DlTps589 from D. Lanceolata

The DNA sequences of one of the selected sesquiterpene synthases DlTps589 was codon-optimized, synthesized in-vitro and cloned in the pJ444-SR expression plasmid (DNA2.0, Menlo Park, Calif., USA).

Heterologous expression of the DlTps589 synthases was performed in KRX E. coli cells (Promega). Single colonies of cells transformed with the pJ444SR-DlTps589 expression plasmid were used to inoculate 5 ml LB medium. After 5 to 6 hours incubation at 37° C., the cultures were transferred to a 20° C. incubator and left 1 hour for equilibration. Expression of the protein was then induced by the addition of 1 mM IPTG and 0.2% L-rhamnose and the culture was incubated over-night at 20° C. The next day, the cells were collected by centrifugation, resuspended in 0.1 volume of 50 mM MOPSO pH 7, 10% glycerol and lyzed by sonication. The extracts were cleared by centrifugation (30 min at 20,000 g) and the supernatants containing the soluble proteins were used for further experiments.

The crude E coli protein extracts containing the recombinant protein were used for the characterization of the enzymatic activities. The assays were performed in 2 mL of 50 mM MOPSO pH 7, 10% glycerol, 1 mM DTT, 15 mM MgCl₂in the presence of 80 μM of farnesyl-diphosphate (FPP, Sigma) and 0.1 to 0.5 mg of crude protein. The tubes were incubated 12 to 24 hours at 30° C. and extracted twice with one volume of pentane. After concentration under a nitrogen flux, the extracts were analysed by GC and GC-MS and compared to extracts from assays with control proteins. The analysis of the products formed by the enzymes was made by GCMS as described in example 1. A negative control was performed in the same conditions using E. coli cells transformed with an empty pJ444 plasmid. In these conditions, the DlTps589 recombinant enzyme produced (−)-drimenol as major product with a selectivity over 98% (FIG. 2). The identity of (−)-drimenol was confirmed by matching of the mass spectrum and retention time of an authentic Drimenol standard isolated from Sandalwood Oil West (Amyris balsamifera).

Example 3. In Vivo Production of (−)-Drimenol in E. coli Cells Using DlTps589

To evaluate the in-vivo production of (−)-drimenol in heterologous cells, E. coli cells were transformed with the pJ444SR-DlTps589 expression plasmid and the production of sesquiterpenes from the endogenous FPP pool was evaluated. To increase the productivity of the cells, an heterologous FPP synthase and an the enzymes from a complete heterologous mevalonate (MVA) pathway were also expressed in the same cells. The construction of the expression plasmid containing an FPP synthase gene and the gene for a complete MVA pathway was described in patent WO2013064411 or in Schalk et al (2013) J. Am. Chem. Soc. 134, 18900-18903. Briefly, an expression plasmid was prepared containing two operons composed of the genes encoding the enzymes for a complete mevalonate pathway. A first synthetic operon consisting of an E. coli acetoacetyl-CoA thiolase (atoB), a Staphylococcus aureus HMG-CoA synthase (mvaS), a Staphylococcus aureus HMG-CoA reductase (mvaA) and a Saccharomyces cerevisiae FPP synthase (ERG20) genes was synthetized in-vitro (DNA2.0, Menlo Park, Calif., USA) and ligated into the Ncol-BamHI digested pACYCDuet-1 vector (Invitrogen) yielding pACYC-29258. A second operon containing a mevalonate kinase (MvaK1), a phosphomevalonate kinase (MvaK2), a mevalonate diphosphate decarboxylase (MvaD), and an isopentenyl diphosphate isomerase (idi) was amplified from genomic DNA of Streptococcus pneumoniae (ATCC BAA-334) and ligated into the second multicloning site of pACYC-29258 providing the plasmid pACYC-29258-4506. This plasmid thus contains the genes encoding all enzymes of the biosynthetic pathway leading from acetyl-coenzyme A to FPP.

KRX E. coli cells (Promega) were co-transformed with the plasmid pACYC-29258-4506 and the plasmid pJ444SR-DlTps589. Transformed cells were selected on carbenicillin (50 μg/ml) and chloramphenicol (34 μg/ml) LB-agarose plates. Single colonies were used to inoculate 5 mL liquid LB medium supplemented with the same antibiotics. The culture was incubated overnight at 37° C. The next day 2 mL of TB medium supplemented with the same antibiotics were inoculated with 0.2 mL of the overnight culture. After 6 hours incubation at 37° C., the culture was cooled down to 28° C. and 0.1 mM IPTG and 0.2% rhamnose were added to each tube. The cultures were incubated for 48 hours at 28° C. The cultures were then extracted twice with 2 volumes of MTBE, the organic phase were concentrated to 500 μL and analyzed by GC-MS as described above in Example 1.

In this in-vivo conditions the DlTps589 recombinant enzyme produced (−)-drimenol as major product with the same apparent selectivity as in the in vitro assay described in example 2 (FIG. 3). Using these engineered E. Coli cells larger (1 L) culture were used to purified the sesquiterpene produced by the enzyme in sufficient quantity to confirm the structure by NMR analysis and specific rotation measurement as being the structure of (−)-drimenol shown in FIG. 4. The enantiopurity was confirmed by chiral GC analysis on a Varian CP-3800 GC system equipped with a ChiraSil column (Agilent) and using oven gradient temperature of 3.0° C./min from 125 to 180° C. (FIG. 5).

Example 4. Functional Expression and Characterization of SCH51-3228-9 and SCH51-3228-11 from D. Winteri

SCH51-3228-9 and SCH51-3228-11 are two other DNA sequences putatively encoding for sesquiterpene synthases and isolated from the Drymis winteri transcriptome sequences. The deduced amino acid sequences share 92.6 and 95.1% identity, respectively with the DlTps589 amino acid sequence. The two sequences were codon optimized, synthesized in-vitro (Invitrogen) and cloned between the NdeI and KpnI restriction enzyme recognition sites of the pETDuet-1 (Novagen) expression plasmid (Invitrogen).

Heterologous expression of the SCH51-3228-9 and SCH51-3228-11 synthases was performed in BL21 (DE3) E. coli cells (Invitrogen). Single colonies of cells transformed with the pETDuet-SCH51-3228-9 or the pEDTDuet-SCH51-3228-11 expression plasmids were used to produce the recombinant enzymes as described in example 2. The crude E coli protein extracts containing the recombinant proteins were used for the characterization of the enzymatic activities as described in example 2 except for the the GCMS analysis conditions which were performed as follows. The GCMS analysis was made on an Agilent 6890 Series GC system connected to an Agilent 5975 mass detector. The GC was equipped with 0.25 mm inner diameter by 30 m DB-1 ms capillary column (Agilent). The carrier gas was He at a constant flow of 1 mL/min. The initial oven temperature was 50° C. (5 min hold) followed by a gradient of 5° C./min to 300° C. The injection was made in split mode at 250° C. with a split ratio of 5:1.

The The two recombinant enzymes produced (−)-drimenol as major product with high selectivity. The identity of (−)-drimenol was confirmed by matching of the mass spectrum and retention time of an authentic Drimenol standard isolated from Sandalwood Oil West (Amyris balsamifera) (FIG. 6).

Using the whole E. Coli cell system and method described in example 3 (except for the GCMS analysis conditions which were as described above) Drimenol could also be produced in vivo in bacteria cultures using the SCH51-3228-9 and SCH51-3228-11 recombinant proteins (FIG. 7).

Example 5. Functional Expression and Characterization of SCH51-998-28 from D. Winteri and SCH52-13163-6 from D. Lanceolata

Similarly to example 4, the two cDNAs SCH51-998-28 and SCH52-13163-6 were optimized and cloned in the pETDuet expression plasmid.

The recombinant proteins were produced in in BL21 (DE3) E. coli cells (Invitrogen) and the in vitro assays using FPP as substrate were performed as described in example 2 and 4. These assays showed Drimenol synthase activity for SCH51-998-28 and SCH52-13163-6 (FIG. 6). Using E. Coli cells overproducing FPP from a recombinant mevalonate pathway (example 2 and 4), Drimenol could also be produced in vivo using the SCH51-998-28 and SCH52-13163-6 proteins (FIG. 7).

Example 6. Sequence Comparison of the Drimenol Synthases from Drimys Species

The amino acid sequences of the Drimenol synthases from Drimys winteri and Drimys lanceolata were aligned using the ClustalW Multiple alignment program (Thompson et al, 1994, Nucleic Acid Res. 22(22), 4673-4680 and the sequence identities were calculated based on this alignment.

Percent identity (%) between the different Drimenol synthases from Drimys species:

SCH51- SCH51- SCH51- SCH52- DITps589 3228-11 3228-9 998-28 13163-6 DITps589 ID 95.1 92.6 70.5 88 SCH51_3228_11 95.1 ID 97.1 70.6 87.6 SCH51_3228_9 92.6 97 ID 71 90.1 SCH51_998_28 70.5 70.6 0.71 ID 72.5 SCH52_13163_6 88 87.6 90.1 72.5 ID

Claims

1. A method of producing drimenol comprising:

i) contacting farnesyl diphosphate (FPP) with a polypeptide having drimenol synthase activity and comprising an amino acid sequence having at least 85% sequence identity to a sequence selected from the group consisting of SEQ ID NO: 2 and SEQ ID NO: 5 to produce the drimenol; and

ii) optionally isolating the drimenol.

2. The method as recited in claim 1 wherein the drimenol is isolated.

3. The method as recited in claim 1 wherein the drimenol is produced with at least 30% selectivity.

4. The method as recited in claim 1 comprising the steps of transforming a host cell or non-human organism with a nucleic acid encoding a polypeptide comprising an amino acid sequence having at least 85% sequence identity of a sequence selected from the group consisting of SEQ ID NO: 2 and SEQ ID NO: 5 and culturing the host cell or organism under conditions that allow for the production of the polypeptide.

5. The method recited in claim 4 wherein the cell is a prokaryotic cell or a eukaryotic cell.

6. The method as recited in claim 4 wherein the cell is a bacterial cell.

7. The method as recited in claim 5 wherein the eukaryotic cell is a yeast cell or a plant cell.

8. The method as recited in claim 2 wherein the drimenol is produced with at least 30% selectivity.